Erythropoietin: new horizon in cardiovascular medicine.
Erythropoietin: new horizon in cardiovascular medicine.
复制标题
DOI：
10.2174/157489007779606112
复制
发表时间：
2007-01-01
期刊：
影响因子：
--
通讯作者：
Scarabelli, Tiziano M
中科院分区：
文献类型：
--
作者：
Koul, Deepak;Dhar, Sunil;Scarabelli, Tiziano M
促红细胞生成素（EPO）是一种肾脏细胞因子，调节红系细胞的增殖、分化和成熟。重组人促红细胞生成素（rH-EPO）是众所周知的，以纠正贫血的慢性肾功能衰竭患者进行透析。最近的研究报道了EPO的几种非造血作用。促红细胞生成素受体已在多种组织中发现，包括心血管系统。最近发表的数据（包括最近的专利）记录了接受EPO治疗的心力衰竭患者的心脏功能增强。此外，在局部缺血/再灌注（IR）损伤的动物模型中进行的实验显示，EPO治疗后梗死面积显著减小。EPO的其他有益作用与其对内皮细胞的促血管生成作用有关，这可能在缺血性心脏病患者中具有潜在价值。总之，这些发现表明，EPO可能是临床上有用的辅助治疗不同的心血管疾病，除了简单的纠正贫血。本文就促红细胞生成素在心血管系统中的多效性作用及其应用前景作一综述。
Erythropoietin (EPO), a renal cytokine, regulates proliferation, differentiation and maturation of erythroid cells. Recombinant human erythropoietin (rH-EPO) is well known to correct anemia in patients with chronic renal failure undergoing dialysis. Recent studies have reported several non-hematopoietical effects of EPO. Erythropoietin receptors have been discovered in a variety of tissues, including the cardiovascular system. Recently published data including recent patent documented an enhancement of cardiac function in patients with heart failure receiving EPO treatment. Furthermore, experiments carried out in animal models of ischemia/reperfusion (IR) injury have shown a significant reduction in infarct size following EPO treatment. Other beneficial effects of EPO are related to its pro-angiogenic action on endothelial cells, which might be of potential value in patients with ischemic heart disease. Taken together, these findings suggest that EPO may be clinically useful as an adjunct in the treatment of different cardiovascular conditions, besides the simple correction of anemia. This review will focus on the pleiotropic effects of EPO in the cardiovascular system and its promising novel applications.